Express

(redirected from expressers)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

Express

Clear; definite; explicit; plain; direct; unmistakable; not dubious or ambiguous. Declared in terms; set forth in words. Directly and distinctly stated. Made known distinctly and explicitly, and not left to inference. Manifested by direct and appropriate language, as distinguished from that which is inferred from conduct. The word is usually contrasted with implied.

That which is express is laid out in words, such as an express Warranty, which is an oral or written affirmation from a seller to a buyer of goods that certain standards will be met. Such a warranty may include the promise that any defect which occurs during a certain specified time period will be remedied at the seller's expense. This is distinguishable from an Implied Warranty, which is neither written nor based on any specific oral statement from seller to buyer but is implied through the sale itself. A common example is the implied warranty of merchantability, which implies that an item is fit for the usual purposes for which it was purchased.

Express authority is plainly or distinctly delegated power to an agent by a principal. For example, the owner of a store may expressly give employees the authority to accept deliveries in the owner's name.

express

adj. direct, unambiguous, distinct language, particularly in a contract, which does not require thought, guessing, inference or implication to determine the meaning.

EXPRESS. That which is made known, and not left to implication. The opposite of implied. It is a rule, that when a matter or thing is expressed, it ceases to be implied by law: expressum facit cessare tacitum. Co. Litt. 183; 1 Bouv. Inst. n. 97.

References in periodicals archive ?
Overall survival of lung cancer and gastrin-releasing peptide receptor (GRPR) expressers calculated using the Kaplan-Meier survival curves.
In only 16 of 235 cases (1 early cancer and 15 advanced carcinomas) did the tumor cells show complete absence of staining; these were classified as CTGF low expressers. Of the 51 chronic cholecystitis analyzed, 49 (96%) had low CTGF expression, whereas only 2 (4%) showed high CTGF levels.
CYP3A5 high expressers had lower mean tacrolimus concentrations during the first week after renal transplantation, and rejection occurred earlier in these patients (23).
We therefore set out to assess the relative contributions of CYP3A5 and CYP3A4 to the formation of the main tacrolimus metabolite (13-O-demethyltacrolimus), using cDNA-expressed enzymes and a bank of human liver microsomes derived from low and high CYP3A5 expressers.
HG03, HG64, and HG74 (CYP3A5 low expressers), and HH31, HH54, HH47, HH91, HG95, HH108, HH86, HH3, HH1, HH89, HH48, and HH9 (CYP3A5 high expressers)] and baculovirus-derived microsomes producing CYP1A2/OR (cat.
We next investigated the tacrolimus 13-O-demethylation activity in a bank of 15 human liver samples, including 12 high expressers and 3 low expressers for CYP3A5.
When we used the relative activity factor approach (29) and the parallel-tube model, the predicted tacrolimus 13-O-demethylation clearance values ([CL.sub.p2]) in livers from CYP3A5 high and low expressers were, on average, 8.60 and 3.57 mL * [min.sup.-1] * [(kg of body weight).sup.-1], respectively (P = 0.0088, Mann-Whitney U-test; Fig.
The contribution of CYP3A5 to the 13-O-demethylation of tacrolimus in HLMs varied from 1.5% to 40% and was particularly strong in livers with low CYP3A4, whereas it was lower in those with high CYP3A4 and in the 3 CYP3A5 low expressers. These findings support the observations that CYP3A5 is an important source of interindividual variability for CYP3A when CYP3A5 content represents a significant fraction of the total hepatic CYP3A pool (36, 38, 41).
In our hands, the mean predicted tacrolimus pharmacokinetic clearances in CYP3A5 low expressers (3.57 mL * [min.sup.-1] * [kg.sup.-1]) and CYP3A5 high expressers (8.60 mL * [min.sup.-1] * [kg.sup.-1]) were in general in the same range as in vivo (0.68-6 mL * [min.sup.-1] * [kg.sup.-1]) (2).
Furthermore, our data offer an explanation for the substantial variability in tacrolimus dosage independent of CYP3A5 genotype, i.e., that observed within the groups of high and low CYP3A5 expressers (14).
CYP3A5 expressers had higher metabolism of lovastatin, simvastatin, and atorvastatin (49), whereas no association was found between the polymorphism and efficacy of statins that are not metabolized by CYP3A5 (fluvastatin and pravastatin).
This is in agreement with the finding that 10% of Caucasians were high expressers of CYP3A5 (7).